Protagonist Therapeutics, Inc. (PTGX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 25.70 |
| Open | 25.13 |
| Bid | 24.62 x 200 |
| Ask | 24.69 x 200 |
| Day's range | 24.52 - 25.14 |
| 52-week range | 13.72 - 33.34 |
| Volume | |
| Avg. volume | 665,940 |
| Market cap | 1.437B |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GuruFocus.com
Protagonist Therapeutics Inc CEO Sells 25,000 Shares
Protagonist Therapeutics Inc (NASDAQ:PTGX), a biopharmaceutical company, has reported an insider sale according to a recent SEC filing.
- Simply Wall St.
Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%
Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders might be concerned after seeing the share price drop 10% in...
© 2024 Yahoo. All rights reserved.